These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24113274)

  • 1. Ocriplasmin: a medical or surgical therapy?
    Duker JS; Moshfeghi AA
    Retina; 2013; 33(10):2001-2. PubMed ID: 24113274
    [No Abstract]   [Full Text] [Related]  

  • 2. Injectable drug may help avoid eye surgery in patients with vitreomacular adhesion.
    Morrow T
    Manag Care; 2013 Jan; 22(1):49-50. PubMed ID: 23373143
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
    Kim JE
    JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
    [No Abstract]   [Full Text] [Related]  

  • 4. Lamellar macular hole after intravitreal ocriplasmin injection.
    Chod RB; Goodrich C; Saxena S; Akduman L
    BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25576512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter S; Mennel S
    Acta Ophthalmol; 2018 May; 96(3):e409-e411. PubMed ID: 28771974
    [No Abstract]   [Full Text] [Related]  

  • 7. Initial experience with ocriplasmin in the treatment of vitreomacular traction.
    Garcia JM; Isaac DL; Ávila M
    Arq Bras Oftalmol; 2016 Apr; 79(2):85-7. PubMed ID: 27224069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial.
    Stalmans P; Girach A
    Invest Ophthalmol Vis Sci; 2013 Oct; 54(10):6620-7. PubMed ID: 23982845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF INTRAVITREAL OCRIPLASMIN IN PEDIATRIC PATIENTS SCHEDULED FOR VITRECTOMY.
    Drenser K; Girach A; Capone A
    Retina; 2016 Mar; 36(3):565-75. PubMed ID: 26398685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
    Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 12. Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.
    Ober MD; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):113-6; discussion p.113. PubMed ID: 23510035
    [No Abstract]   [Full Text] [Related]  

  • 13. Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin.
    Barteselli G; Carini E; Invernizzi A; Ratiglia R; Viola F
    Acta Ophthalmol; 2016 Mar; 94(2):e160-2. PubMed ID: 26010219
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.
    Kim BT; Schwartz SG; Smiddy WE; Doshi RR; Kovach JL; Berrocal AM; Moshfeghi AA; Fortun JA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(4):334-43. PubMed ID: 23883268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
    Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM
    Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
    Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
    Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
    Liang IC; Wang K; Chien HW; Lin SY
    Indian J Ophthalmol; 2016 Mar; 64(3):222-4. PubMed ID: 27146933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking at ocriplasmin as a new option in eye disease.
    Mitchell MD; Miller DM
    Drugs Today (Barc); 2012 Aug; 48(8):519-24. PubMed ID: 22916339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
    Katz RS
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research update of ocriplasmin for symptomatic vitreomacular adhesion].
    Zhang M; Chen Y
    Zhonghua Yan Ke Za Zhi; 2014 Nov; 50(11):866-70. PubMed ID: 25582211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.